BR0316324A - Polipeptìdeos e conjugados de interferon-alfa - Google Patents

Polipeptìdeos e conjugados de interferon-alfa

Info

Publication number
BR0316324A
BR0316324A BR0316324-5A BR0316324A BR0316324A BR 0316324 A BR0316324 A BR 0316324A BR 0316324 A BR0316324 A BR 0316324A BR 0316324 A BR0316324 A BR 0316324A
Authority
BR
Brazil
Prior art keywords
conjugates
polypeptides
interferon
nucleic acids
alpha polypeptides
Prior art date
Application number
BR0316324-5A
Other languages
English (en)
Inventor
Philip A Patten
Sridhar Govindarajan
Sridhar Viswanathan
Torben Lauesgaard Nissen
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of BR0316324A publication Critical patent/BR0316324A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"POLIPEPTìDEOS E CONJUGADOS DE INTERFERON-ALFA". A presente invenção fornece polipeptídeos e conjugados de interferon-alfa e ácidos nucleicos que codificam os polipeptídeos. A invenção também inclui composições que compreendem esses polipeptídeos, conjugados e ácidos nucleicos; células contendo ou expressando os polipeptídeos, conjugados e ácidos nucleicos; métodos de fabricação dos polipeptídeos, conjugados e ácidos nucleicos; e métodos de uso dos polipeptídeos, conjugados e ácidos nucleicos.
BR0316324-5A 2002-11-18 2003-11-17 Polipeptìdeos e conjugados de interferon-alfa BR0316324A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42761202P 2002-11-18 2002-11-18
US50256003P 2003-09-12 2003-09-12
PCT/US2003/036682 WO2004046365A2 (en) 2002-11-18 2003-11-17 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
BR0316324A true BR0316324A (pt) 2005-09-27

Family

ID=32329174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316324-5A BR0316324A (pt) 2002-11-18 2003-11-17 Polipeptìdeos e conjugados de interferon-alfa

Country Status (13)

Country Link
US (1) US20040219131A1 (pt)
EP (1) EP1565205A4 (pt)
JP (1) JP2006506097A (pt)
KR (1) KR20050086498A (pt)
AU (1) AU2003297285A1 (pt)
BR (1) BR0316324A (pt)
CA (1) CA2504267A1 (pt)
IL (1) IL168049A0 (pt)
MX (1) MXPA05005263A (pt)
NO (1) NO20052363L (pt)
NZ (1) NZ540043A (pt)
RU (1) RU2005118998A (pt)
WO (1) WO2004046365A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EA008866B1 (ru) 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EP1597278A4 (en) * 2003-02-26 2006-03-22 Intermune Inc COMPOSITIONS OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON AND METHOD FOR THE APPLICATION THEREOF
CN1934143B (zh) 2004-01-21 2010-10-20 耐科塔医药公司 丙酸封端聚合物的制备方法
AU2005245918A1 (en) * 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
EP1771197A2 (en) * 2004-06-30 2007-04-11 Egen Corporation Pegylated interferon alpha-1b
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP1817413B1 (en) 2004-11-11 2012-01-04 Modular Genetics, Inc. Oligonucleotide ladder assembly and system for generating molecular diversity
US9931413B2 (en) * 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
CN101501068A (zh) * 2005-05-18 2009-08-05 马克西根公司 改进的α-干扰素多肽
EP2061515A4 (en) 2006-09-14 2013-01-30 Medgenics Medical Israel Ltd LONG-TERM MEDICINAL FORMULATIONS
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN1970572A (zh) * 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
EP2582396A4 (en) 2010-06-15 2014-01-01 Medgenics Medical Israel Ltd REMEDY FORMULATIONS WITH LONG-TERM EFFECT
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
AU2022328512A1 (en) * 2021-08-18 2024-03-28 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
RU2005118752A (ru) * 2002-11-15 2006-02-10 Ф.Хоффманн-Ля Рош Аг (Ch) Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)

Also Published As

Publication number Publication date
KR20050086498A (ko) 2005-08-30
WO2004046365A2 (en) 2004-06-03
NO20052363D0 (no) 2005-05-12
EP1565205A2 (en) 2005-08-24
NZ540043A (en) 2007-11-30
US20040219131A1 (en) 2004-11-04
EP1565205A4 (en) 2006-07-05
RU2005118998A (ru) 2006-01-27
MXPA05005263A (es) 2005-07-25
IL168049A0 (en) 2009-02-11
JP2006506097A (ja) 2006-02-23
NO20052363L (no) 2005-08-08
CA2504267A1 (en) 2004-06-03
WO2004046365A3 (en) 2004-09-02
AU2003297285A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
NO20010013L (no) Svovelsubstituerte sulfonylaminokarboksylsyre N-arylamider, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
TW200611910A (en) Interferon-alpha polypeptides and conjugates
DE69841285D1 (de) Bipolares Elektrodeninstrument
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
ATE376568T1 (de) Epoxy-polysiloxan polymerzusammensetzung
DE69810287D1 (de) Flüssige härtbare harzzusammensetzung
DE60010098D1 (de) 28-epirapaloge
DE69941559D1 (de) Enzymgemisch
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
DE69935623D1 (de) Härtbare Harzzusammensetzung
FI892377A0 (fi) Ny polymerkomposition.
DE69911530D1 (de) Härtbare Siliconzusammensetzung
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
DE69917370D1 (de) Verwendung von disubstituierten Ethylen-Maleimid-Copolymeren in Kautschuk-Zusammensetzungen
DE69915204D1 (de) Stabilisierte Proteinzusammensetzung
DE69606414D1 (de) In Gegenwart von Wasser oder Luftfeuchtigkeit härtbare Siliconzusammensetzungen
DE69925820D1 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
DE69811794D1 (de) Härtbare Gummizusammensetzung
DE69822711D1 (de) Verfarhen zur Herstellung von Dialkylnaphthalinen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
SE9602822D0 (sv) New receptor
EP0914140A4 (en) ANTIOXIDAL PROTEINS SPECIFIC TO LARVAE THIOL OF PARASITIC HELMINTHES, NUCLEIC ACID MOLECULES AND USES THEREOF
DE59811071D1 (de) Präparation umfassend Thiolgruppen-haltige Proteine
ID27133A (id) Derivat-derivat asam sulfonilaminofin dan fosfonat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]